Wrap up: FTC vacates ban on noncompete agreements, and other news

Happy Friday dvm360 readers! Have you gotten a chance to check out dvm360.com’s new look? On Monday, we officially launched our new website, which has plenty of new features and a new look, including a section dedicated to shorter videos. Have an idea of what you would want to see there? Email our team at news@dvm360.com!

Since you are already checking out the website, here is some news that was posted this week!

• The Federal Trade Commission recently announced that in a 3-1 vote, it has vacated the 2024 final rule banning most employment noncompete agreements, meaning the initiative from the Biden Administration has formally ended.
• Health Canada approved fluralaner for extended-release injectable suspension (Bravecto Quantum; Merck Animal Health), becoming one of the over 50 countries in the world to approve the product to treat and prevent flea infestations, as well as treat and control tick infestations for 12 months in dogs and puppies over 6 months of age.
• On this week’s episode of The Vet Blast Podcast presented by dvm360, Matthew W. Brunke, DVM, DACVSMR (Canine), CCAT, Fellow IAVRPT, and Adam Christman, DVM, MBA, talked about the modern multimodal pain management for patients, including joint therapies and evidence-based holistic approaches, and more.
• Pet Poison Helpline shared the story of Rocky, a Pomeranian, who tested positive for cocaine, amphetamines, and tetrahydrocannabinol—the psychoactive compound in marijuana—after being exposed at a music festival.
• A study from the University of Maryland found that antiviral treatment with oseltamivir and identifying highly pathogenic avian influenza virus (H5N1) early in feline patients can help improve survival rates after studying 4 cats in one home infected with the virus.
• And more!